Azenta (AZTA) Q3 FY26 earnings call: guidance and Q&A

Inquired about the drivers of Multiomics North America improvement (demand vs. execution) and confidence in sustained recovery given initiatives.

John Marotta attributed improvement to catch-up of delayed projects (NIH-funded), accretive sales investments, new commercial leadership, and timing of a $3M clinical services order. Lawrence Lin added that while encouraging, it's not yet evidence of broad-based sustained market recovery.

“Q3 was certainly an encouraging quarter, and we're really pleased with the execution across the businesses. Revenue grew 9% organically. And our adjusted EBITDA exceeded consensus.”

asked by David Saxon · answered by John P. Marotta

Asked for a bridge of the FY26 EBITDA margin guide and whether UKBC's 30bps dilution is a good starting point for FY27.

Lawrence Lin outlined Q4 EBITDA drivers including mix benefit from SMS, better fixed cost absorption in Multiomics, and cost optimization in stores/Sanger, partially offset by higher bonus and accelerated commercial investments. He noted $5M in quality issues and $5M in strategic investments as non-recurring for FY27, suggesting a 'resting heart rate' around the mid-70s. UKBC's 30bps dilution is for FY26, expected to be accretive next year.

“what doesn't reoccur, $5 million of quality issues as we've talked out, we went through that process this year. I would say about strategic investments is about $5 million and some onetime items such as E&O and mix. So that gives you a better, let's call it, resting heart rate around the mid-70s as a jump-off point.”

asked by David Saxon · answered by Lawrence Lin

Inquired about order trends and customer activity levels for Q4 and into next year, distinguishing between short-cycle (Multiomics, C&I) and longer-cycle (stores) businesses.

John Marotta noted strong double-digit growth and momentum in Multiomics China and Europe (Gene Synthesis, NGS). C&I and SRS have nice growth and long-term visibility due to recurring revenue. Automated stores and cryo still face lumpiness and challenges in converting a healthy pipeline, with more CapEx release in Europe and the Middle East than North America.

“a lot of positivity in our in our businesses in China and Europe on all of our product lines. We're seeing double-digit growth in Gene Synthesis, specifically in China and Europe, a lot of good momentum there.”

asked by Matthew Stanton · answered by John P. Marotta

Asked about the durability of strong Multiomics performance in Europe and China, drivers, and whether it's biotech/pharma or academic/government.

John Marotta expressed confidence in the durability of strength in Multiomics Europe and China, citing productivity gains from commercial investments. He noted that these regions are performing well and are 'on the launching pad.'

“a lot of durability there. We feel pretty good about -- we're on the launching pad with China and Europe specifically in multiomics. Those regions are performing well.”

asked by Matthew Stanton · answered by John P. Marotta

Asked what the key gating factor is for client interest in equipment converting to more durable orders.

John Marotta cited a 'healthy tension' between onshoring bioprocessing and CapEx investments. He emphasized controlling what they can by optimizing cost structure, simplifying and standardizing offerings, and focusing on high-value opportunities to scale the business.

“There's a healthy tension between the onshoring bioprocessing and some of the CapEx investments that are in these larger equipment items such as ours, I think that's going to continue right now with some of the onshoring trends.”

asked by Steven Etoch · answered by John P. Marotta

Asked about the modular stores business, its simplicity, and lower risk compared to the previously unpredictable product line.

John Marotta explained that modularity converts 'one-off' customizations to configurable options based on 5 key customer needs (density, throughput, footprint, labware, temperature). This standardization aims to improve quality and reduce execution risk. He also mentioned developing smaller kiosks to link with larger stores.

“what do customers care most about right now? Customers care most about density of storage, throughput, footprint and lastly, what labware can they use. And so overlay that with the temperature elements. There's really 5 key components that they care about, and we're overlapping that so they can configure the store meaning what do they need in those 5 elements, okay?”

asked by Paul Knight · answered by John P. Marotta

Inquired about the priority of BD in capital allocation, types of BD considered, and whether long-term goals (e.g., 2029 top-line growth) are still under review.

Lawrence Lin stated they remain disciplined on M&A, pursuing opportunities that create value and not just deploying capital. He highlighted the balance between M&A and share repurchases. Regarding long-term goals, he reiterated focus on Investor Day priorities, especially recurring revenue businesses, and stabilizing Multiomics. He confirmed confidence in hitting the full LRP basis and achieving 18% to 20% adjusted EBITDA margin.

“we'll certainly hit the full year -- a full LRP basis and get to 18% to 20% that we've talked about.”

asked by Brendan Smith · answered by Lawrence Lin